Saturday 17 October 2026
Export BVS’s income statement to Excel — free account
Bioventus Inc.
BVS Healthcare Medical Devices
Bioventus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $568.1 million, down 0.91% from fiscal 2024. In the quarter to June 2026, revenue grew 3.76%, EPS grew 345.5%, free cash flow fell 25.1% and total debt fell 27.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
13.30
0.51
−3.69%
Follow BVS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
11.65 | 21.23 | 21.88 | 55.75 |
+8 more quarters Free account |
P/S ratio |
1.10 | 1.07 | 0.87 | 0.79 | |
P/FCF ratio |
6.80 | 6.11 | 6.87 | 8.37 | |
P/Operating CF |
32.24 | 68.77 | 13.06 | 14.88 | |
P/B ratio |
2.31 | 2.62 | 2.17 | 2.16 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.48 | 1.48 | 1.30 | 1.29 | |
EV/EBITDA |
8.30 | 8.19 | 7.31 | 8.10 | |
EV/Operating CF |
8.87 | 8.26 | 9.89 | 13.00 | |
EV/FCF |
9.12 | 8.45 | 10.24 | 13.62 | |
Quick Ratio |
1.10 | 1.06 | 1.12 | 1.07 | |
Current Ratio |
1.69 | 1.69 | 1.70 | 1.74 | |
Net Debt/EBITDA |
7.28 | 12.04 | 7.78 | 12.38 | |
Debt/Assets |
36.90% | 41.82% | 43.00% | 45.98% | |
Debt/Equity |
0.90 | 1.16 | 1.29 | 1.56 | |
Asset Turnover |
0.84 | 0.86 | 0.80 | 0.77 | |
Operating CF/Net income |
0.59 | 2.87 | 2.57 | 9.54 | |
Capex/Depreciation |
(0.09) | (0.05) | (0.05) | (0.04) | |
Interest Coverage |
4.70 | 1.95 | 3.67 | 1.82 | |
Research and Development Expense of Revenue |
2.07% | 1.87% | 1.90% | 2.11% | |
Selling, General and Administrative Expense of Revenue |
54.01% | 59.30% | 52.41% | 56.73% | |
Intangible Assets out of Total Assets |
0.53 | 0.56 | 0.55 | 0.55 | |
Share Based Compensation of Revenue |
3.29% | 2.47% | 2.18% | 2.29% | |
Graham Net Nets |
(0.22) | (0.27) | (0.37) | (0.48) | |
Graham Number |
8.63 | 5.80 | 5.12 | 2.89 | |
Earnings Yield |
8.58% | 4.71% | 4.57% | 1.79% | |
Free Cash Flow Yield |
14.72% | 16.38% | 14.55% | 11.94% | |
Revenue per Share |
2.26 | 1.96 | 2.37 | 2.07 | |
Operating CF per Share |
0.29 | 0.13 | 0.57 | 0.45 | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Free Cash Flow per Share |
0.28 | 0.12 | 0.56 | 0.44 | |
Cash per Share |
0.43 | 0.53 | 0.77 | 0.63 | |
Shareholders Equity per Share |
4.09 | 3.48 | 3.43 | 3.10 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.09 | 3.48 | 3.43 | 3.10 | |
Free Cash Flow |
18.91 | 8.36 | 37.39 | 29.63 | |
Working Capital |
105.08 | 101.72 | 112.46 | 119.15 | |
Capital Expenditures |
(0.96) | (0.57) | (0.58) | (0.47) | |
Net Current Asset Value |
(138.41) | (166.46) | (182.27) | (213.44) | |
EV/EBIT |
14.75 | 14.79 | 13.68 | 17.26 | |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
10.99 | 10.68 | 9.18 | 10.61 | |
| Other line items | |||||
Average Receivables |
135.39 | 119.30 | 127.85 | 126.16 | |
Average Payables |
22.22 | 21.62 | 17.31 | 21.75 | |
Average Inventory |
88.14 | 88.62 | 87.36 | 93.15 | |
Average Assets |
690.07 | 670.98 | 705.76 | 735.54 | |
Average Common Equity |
239.36 | 209.87 | 207.03 | 197.04 |
Columns are period end dates